Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017198877) POLYPEPTIDES MODULATING SIGLEC DEPENDENT IMMUNE RESPONSES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/198877 International Application No.: PCT/EP2017/062295
Publication Date: 23.11.2017 International Filing Date: 22.05.2017
IPC:
A61K 38/00 (2006.01) ,A61K 38/36 (2006.01) ,A61K 38/37 (2006.01) ,C07K 14/755 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
36
Blood coagulation or fibrinolysis factors
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
36
Blood coagulation or fibrinolysis factors
37
Factors VIII
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
745
Blood coagulation or fibrinolysis factors
755
Factors VIII
Applicants:
OCTAPHARMA AG [CH/CH]; Seidenstraße 2 8853 Lachen, CH
Inventors:
KANNICHT, Christoph; DE
WINGE, Stefan; SE
KOHLA, Guido; DE
SOLECKA-WITULSKA, Barbara; DE
Agent:
ULLRICH & NAUMANN; Schneidmühlstraße 21 69115 Heidelberg, DE
Priority Data:
16170690.820.05.2016EP
Title (EN) POLYPEPTIDES MODULATING SIGLEC DEPENDENT IMMUNE RESPONSES
(FR) POLYPEPTIDES MODULANT LES RÉPONSES IMMUNITAIRES DÉPENDANTES DE SIGLEC
Abstract:
(EN) The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.
(FR) La présente invention concerne un polypeptide glycosylé comprenant une séquence d'acides aminés identique ou homologue à au moins un fragment d'un mammifère, de préférence une protéine humaine, ledit polypeptide glycosylé contenant un ou plusieurs O-glycanes sialylés, et le polypeptide glycosylé présentant une affinité de liaison augmentée à un ou plusieurs SIGLEC, choisis parmi SIG-5, SIG-7, SIG-8 et SIG-9 par rapport à la protéine de mammifère ou un fragment de celle-ci. L'invention concerne en outre une composition comprenant un premier et un deuxième polypeptide, le premier polypeptide étant un polypeptide glycosylé contenant un ou plusieurs O-glycanes sialylés et le deuxième polypeptide contenant une séquence d'acides aminés homologue ou identique à une deuxième protéine de mammifère, en particulier humaine, dans laquelle, par rapport au deuxième polypeptide, la composition a une affinité de liaison augmentée à un SIGLEC choisi parmi un ou plusieurs SIGLEC, choisis parmi SIG-5, SIG-7, SIG-8 et SIG-9.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)